D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024
February 13, 2024 at 06:45 pm EST
Share
D. Western Therapeutics Institute, Inc. provided consolidated earnings guidance for the full year ending December 31, 2024. For the full year on consolidated basis, the company expected net sales of JPY 400 million, operating loss of JPY 1,500 million, loss attributable to owners of parent of JPY 1,510 million and loss per share of JPY 47.00.
For the full year on non consolidated basis, the company expected net sales of JPY 400 million, loss of JPY 1,450 million, and loss per share of JPY 45.13.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 
